Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
